Pirtobrutinib als erster nichtkovalenter BTKi bei r/r CLL zugelassen

Im Focus Onkologie 2026

View at publisher
Authors: Claudia Schöllmann
DOI: 10.1007/s15015-025-4485-6
Cited by: 0

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Acute Lymphoblastic Leukemia research

Publication details

Journal / source
Im Focus Onkologie
Volume
29
Issue
1-2
Pages
54–54
Publication date
1 February 2026
Language
DE